Compare UCTT & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCTT | WVE |
|---|---|---|
| Founded | 1991 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 2004 | 2015 |
| Metric | UCTT | WVE |
|---|---|---|
| Price | $50.80 | $13.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 15 |
| Target Price | ★ $75.00 | $30.73 |
| AVG Volume (30 Days) | 1.7M | ★ 2.2M |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,734,500,000.00 | $3,704,000.00 |
| Revenue This Year | $19.18 | $16.76 |
| Revenue Next Year | $17.36 | $149.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $16.66 | $5.28 |
| 52 Week High | $73.80 | $21.73 |
| Indicator | UCTT | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 45.12 | 45.40 |
| Support Level | $22.71 | $12.53 |
| Resistance Level | $58.70 | $14.56 |
| Average True Range (ATR) | 5.11 | 0.78 |
| MACD | -1.64 | -0.02 |
| Stochastic Oscillator | 1.84 | 20.34 |
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments Products and Services. Its principal markets are Americas, Asia Pacific and EMEA.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.